173 related articles for article (PubMed ID: 38683834)
1. Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma.
Bijou I; Liu Y; Lu D; Chen J; Sloan S; Alinari L; Lonard DM; O'Malley BW; Wang M; Wang J
PLoS One; 2024; 19(4):e0289902. PubMed ID: 38683834
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma.
Bijou I; Liu Y; Lu D; Chen J; Sloan S; Alinari L; Lonard DM; O'Malley BW; Wang M; Wang J
Res Sq; 2023 Mar; ():. PubMed ID: 36945511
[TBL] [Abstract][Full Text] [Related]
3. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
4. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
Ruella M; Kenderian SS; Shestova O; Fraietta JA; Qayyum S; Zhang Q; Maus MV; Liu X; Nunez-Cruz S; Klichinsky M; Kawalekar OU; Milone M; Lacey SF; Mato A; Schuster SJ; Kalos M; June CH; Gill S; Wasik MA
Clin Cancer Res; 2016 Jun; 22(11):2684-96. PubMed ID: 26819453
[TBL] [Abstract][Full Text] [Related]
5. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
[TBL] [Abstract][Full Text] [Related]
6. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.
Zhao X; Lwin T; Silva A; Shah B; Tao J; Fang B; Zhang L; Fu K; Bi C; Li J; Jiang H; Meads MB; Jacobson T; Silva M; Distler A; Darville L; Zhang L; Han Y; Rebatchouk D; Di Liberto M; Moscinski LC; Koomen JM; Dalton WS; Shain KH; Wang M; Sotomayor E; Tao J
Nat Commun; 2017 Apr; 8():14920. PubMed ID: 28416797
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Guo H; Zeng D; Zhang H; Bell T; Yao J; Liu Y; Huang S; Li CJ; Lorence E; Zhou S; Gong T; Jiang C; Ahmed M; Yao Y; Nomie KJ; Zhang L; Wang M
Oncogene; 2019 Mar; 38(11):1802-1814. PubMed ID: 30361685
[TBL] [Abstract][Full Text] [Related]
8. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
Cheah CY; Chihara D; Romaguera JE; Fowler NH; Seymour JF; Hagemeister FB; Champlin RE; Wang ML
Ann Oncol; 2015 Jun; 26(6):1175-1179. PubMed ID: 25712454
[TBL] [Abstract][Full Text] [Related]
9. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.
Zhao X; Wang MY; Jiang H; Lwin T; Park PM; Gao J; Meads MB; Ren Y; Li T; Sun J; Fahmi NA; Singh S; Sehgal L; Wang X; Silva AS; Sotomayor EM; Shain KH; Cleveland JL; Wang M; Zhang W; Qi J; Shah BD; Tao J
Cell Rep; 2021 Mar; 34(11):108870. PubMed ID: 33730585
[TBL] [Abstract][Full Text] [Related]
11. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
Jacobson C; Kopp N; Layer JV; Redd RA; Tschuri S; Haebe S; van Bodegom D; Bird L; Christie AL; Christodoulou A; Saur A; Tivey T; Zapf S; Bararia D; Zimber-Strobl U; Rodig SJ; Weigert O; Weinstock DM
Blood; 2016 Nov; 128(21):2517-2526. PubMed ID: 27742706
[TBL] [Abstract][Full Text] [Related]
12. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma.
Choi YJ; Kim DH; Yoon DH; Suh C; Choi CM; Lee JC; Hong JY; Rho JK
Sci Rep; 2019 May; 9(1):7193. PubMed ID: 31076643
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib for mantle cell lymphoma.
Tucker DL; Rule SA
Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
[TBL] [Abstract][Full Text] [Related]
15. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
17. MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.
Wu X; Nowakowski KE; Abeykoon JP; Manske M; Stenson MJ; Timm MM; Hanson CA; Van Dyke DL; Dasari S; Witzig TE
Eur J Haematol; 2021 Oct; 107(4):458-465. PubMed ID: 34214199
[TBL] [Abstract][Full Text] [Related]
18. Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma.
Ye H; Huang S; Liu Y; Chen Z; Wang M; Jiang VC
J Cell Mol Med; 2022 May; 26(10):3068-3073. PubMed ID: 35352453
[TBL] [Abstract][Full Text] [Related]
19. Novel therapies for relapsed/refractory mantle cell lymphoma.
Arora PC; Portell CA
Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
[TBL] [Abstract][Full Text] [Related]
20. Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.
Restelli V; Lupi M; Vagni M; Chilà R; Bertoni F; Damia G; Carrassa L
Target Oncol; 2018 Apr; 13(2):235-245. PubMed ID: 29441438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]